CThe Cystic Fibrosis Foundation is a nonprofit nonprofit organization that funds and coordinates medical research and development to treat and cure cystic fibrosis. It does not sell a product; instead, it supports scientists, clinical trials, and patient programs to accelerate discovery and access to therapies. Its work includes funding research, guiding clinical development, and partnering with the CF community to translate scientific advances into treatments that improve health and extend life. The Foundation differentiates itself by its global leadership, large-scale funding, and close collaboration with patients and researchers, which have led to multiple approved CF therapies. Its goal is to enable every person with cystic fibrosis to live a long, healthy life by delivering a cure and reducing the disease’s burden.
Work here?Claim your company
Industries
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Bethesda, MD
Founded
1955
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
NACFC 2026 recap: genetic medicine takes center stage. Members of EE's Scientific Advisory Board (SAB) and leadership at NACFC, from left to right: Patrick Harrison, PhD; Chandra Ghose, PhD, Chief Scientific Officer; Kevin Foskett, PhD; Margarida Amaral, PhD; and Jennifer Bomberger, PhD. From first-of-its-kind personalized gene editing to advances in lung delivery, this year's North American Cystic Fibrosis Conference (NACFC) offered a closer look at the science shaping what's next for the final 10%. What happens when the breakthroughs transforming other genetic diseases begin to converge with cystic fibrosis (CF) research? That question took center stage at the 2026 North American Cystic Fibrosis Conference (NACFC), held October 7-10, 2026, in Atlanta, Georgia. Across plenaries and scientific sessions, researchers explored how advances in gene editing, drug delivery, and clinical trial design could open new possibilities for people with CF who do not benefit from existing CFTR modulators. For the final 10% of the CF community - those unable to benefit from current mutation-targeted therapies - three developments were particularly relevant and offered reasons for optimism. A glimpse of what's possible. One of the conference's most compelling stories came from Kiran Musunuru, MD, PhD, MPH, ML, MRA at the University of Pennsylvania's Perelman School of Medicine, who shared the case of "Baby KJ," an infant with a rare liver disease who received a gene-editing therapy custom-designed for his genetic mutation. The milestone offered a striking example of moving personalized genetic medicine into clinical practice at an unprecedented pace - and a glimpse of what may one day be possible for people with CF, including those with rare CF mutations. The exciting takeaway for the final 10%? While personalized gene editing remains an emerging approach, its success in other diseases offers a valuable foundation for CF researchers to build upon, opening new avenues for people with CF who do not benefit from current mutation-targeted therapies. Adding to that momentum are recently announced plans for a CF gene-editing program in partnership between the Cystic Fibrosis Foundation and Dr. Musunuru that is poised to bring new expertise and attention to the development of genetic therapies for CF, starting with the R553X mutation. The delivery dilemma. If genetic medicine holds the potential to transform CF treatment, getting it to the right cells remains one of the biggest obstacles. James Dahlman, PhD, at Emory University's School of Medicine, and fellow researchers highlighted emerging technologies designed to overcome that challenge, including next-generation lipid nanoparticles (LNPs) and advances in viral capsids that could improve delivery of genetic therapies to the lungs. Why is this so promising for the final 10%? Some genetic therapies, including gene replacement, have the potential to benefit people across different CF mutations. More effective lung delivery could help bring these mutation-agnostic approaches closer to clinical testing... In other words, solving the delivery challenge could help unlock the potential of an entirely new class of CF therapies. Rethinking the road to clinical trials. The scientific progress was accompanied by an equally important conversation: How do Emily's Entourage effectively test the next generation of CF treatments? A dedicated Lunch & Learn session examined innovative clinical trial designs and endpoints, particularly as highly effective modulators reshape the CF landscape. For a small and genetically diverse population such as the final 10%, these questions carry particular weight. Traditional trial approaches can be difficult to implement when eligible patient populations are so small. The encouraging takeaway? Researchers are actively exploring how to adapt clinical trials to this changing landscape. More innovative designs and meaningful measures of treatment effectiveness could make it more feasible to evaluate emerging therapies for smaller populations, helping promising science advance toward the clinic for rare mutations of CF. EE at NACFC: catalyzing collaboration, accelerating breakthroughs. Margarida D. Amaral, PhD (right), recipient of EE's 2026 Dr. Carolyn Denning Trailblazer Award, pictured with Dylan Mortimer (left), the artist who designed the award. For Emily's Entourage (EE), NACFC was also an opportunity to bring together the people specifically focused on turning the scientific advances into real treatment options for the final 10% of the CF community. On Thursday, Oct. 8, EE hosted a special dinner convening leading CF experts for an intimate, productive conversation focused on accelerating therapies for the final 10% and identifying opportunities to move promising approaches into the clinic. Discussions explored which genetic therapies are best positioned for success in the next two years, key clinical trial endpoints, the importance of incorporating participants' lived experiences into efficacy assessments, and priorities for selecting the first clinical trial candidates. The following evening, Friday, Oct. 9, EE hosted its annual NACFC reception, bringing together more than 110 members of the CF research and clinical communities from around the world to connect and hear updates from EE leadership. A highlight of the evening was the announcement of Margarida Amaral, PhD, as EE's 2026 Dr. Carolynn Denning Trailblazer Award recipient, honoring her pioneering contributions to CF research and her role in advancing new possibilities for treatments. From momentum to medicine. With 17 genetic therapies approved across other diseases in recent years, CF researchers have an expanding body of knowledge to build upon. The excitement at NACFC 2026 reflected that progress, alongside a growing focus on the practical challenges ahead. The question is no longer simply what genetic medicine might make possible. It's how researchers can adapt those advances to the unique biology of CF, deliver them effectively, and bring them into clinical trials for the people who need them most - and do it quickly. Now, the challenge is to match this progress with the urgency and determination needed to turn these promising discoveries into lifesaving therapies for the final 10%. It's a challenge EE is working tirelessly to overcome - and one Emily's Entourage won't stop pursuing until every single person with CF has a breakthrough of their own. It was a packed house at the annual EE Reception hosted at 2026 NACFC in Atlanta, Georgia, with more than 110 leading CF researchers and clinicians in attendance.
Choate Construction's Cars & 'Q for the Cause raises over $830K for the Cystic Fibrosis Foundation. Published October 29, 2026 Choate Construction's 17th annual philanthropic event sets a new fundraising record for the Cystic Fibrosis Foundation. Compare Bids Atlanta, GA (PRUnderground) October 29th, 2026 Choate Construction Company's Cars & 'Q for the Cause raised a record $830,758 for the Georgia Chapter of the Cystic Fibrosis Foundation (CFF), crossing $800,000 for the first time in the event's history. The total beats last year's record of $724,144 and pushes Choate's long-standing mission to drive out cystic fibrosis (CF), a genetic lung disease affecting 40,000 people in the U.S. Since 2009, Cars & 'Q for the Cause has raised more than $6.3 million for CFF. On Saturday, October 24, 2026, nearly 1,000 attendees gathered in the parking lot of Choate's Sandy Springs headquarters to "fun" raise for CFF. More than 100 prize-winning automobiles lined the lot, from classic sports cars to muscle, exotic and rare models. Guests enjoyed Jim 'N Nick's BBQ, pours from Mutation Brewing, From the Earth Brewing Company, New Realm Brewing Company, and STATS Brewpub, a silent auction, and live music from The Rogue Tones. Compare Cars "Cars & 'Q started in 2009 as a small group of Choate employees who loved cars. Seeing it cross $800,000 shows how far this community has carried it," said Brian Bollins, Division Manager for Choate Construction in Atlanta. "Every sponsor, donor, vendor, car owner and guest who came out on Saturday had a hand in this number. We couldn't have done it without them or our outstanding crew of volunteers who work tirelessly for this event and those impacted by CF every year." This year's record was made possible by top sponsors Ameris Bank, OnPace Real Estate Partners, The Choate Foundation, Crown Electric, Willis Towers Watson and Paulson-Cheek Mechanical. Orkin B. Associates received this year's Warrior Award, presented on show day to a Cars & 'Q sponsor that has shown steadfast dedication to CFF through its sponsorship and support of the show's mission. The award is named in memory of Leann Rittenbaum Ott, a dear friend of Choate and the original inspiration for the company's fight against cystic fibrosis. Compare Cars "Choate's support for our chapter spans more than three decades, and raising over $800,000 through Cars & 'Q is an extraordinary milestone for the CF community in Georgia," said Vicki Nix, Executive Director, CFF Georgia Chapter. "Breakthrough therapies have raised the median predicted survival age to 65 for people born with CF today, up from 13 when Choate's support began in 1989. But not everyone is eligible for these therapies, and people with CF still face serious complications. Funds raised at Cars & 'Q fuel research in genetic therapies and gene editing as we work toward a cure for every person with CF." Each year, Choate employee-owners support CFF through internal fundraising, with Cars & 'Q as their signature community event. With more than $9.3 million raised since 1989, Choate remains one of CFF's leading corporate partners nationwide. Visit www.carsnq.com to learn more. About Choate Construction Company Known for their proven results and partnership-driven approach, Choate Construction Company's employee-owners provide nationally recognized commercial construction services for their clients and industry partners. Offering the benefits of a nationwide contractor with the dedicated touch of a local firm, Choate Construction's specialized personnel consistently deliver successful projects across a variety of market sectors, including industrial, healthcare, corporate, retail and mixed-use, and more. From its innovative OneLife safety program to its philanthropic efforts to "Build Up" its communities, Choate's ultimate purpose is to enrich the world through the people, places, and relationships it builds. Please visit www.choateco.com for more information. Press Contact. * Name: Zoe Yosanovich * Email: Contact Us PRUnderground. Business News Updates
Reproductive health and cystic fibrosis: New guidance offers options and hope. October 23, 2026 For much of the history of cystic fibrosis (CF) care, reproductive health was not a major part of the conversation. Fertility challenges were the norm for men and women with this genetic disorder, and many grew up assuming biological parenthood was not possible. Clinical visits often focused on more immediate concerns: How is your lung function? Is your weight holding steady? Are symptoms affecting your ability to get through the day? Today, these conversations look markedly different. The introduction of cystic fibrosis transmembrane conductance regulator (CFTR) modulators has transformed the quality of life for many patients with CF. They are living longer, healthier lives, and for many of them, having biological children has become a realistic option. One of the most striking changes has been in fertility among women with CF. After the approval of the triple-combination modulator elexacaftor/tezacaftor/ivacaftor (Trikafta) in 2019 in the U.S. and in 2020 in the U.K., pregnancy rates nearly doubled in those countries. Women who once faced fertility challenges are beginning to conceive naturally, often to their surprise. Clinicians suddenly found themselves navigating questions that previous generations of CF providers rarely encountered. In response, the Cystic Fibrosis Foundation convened a multidisciplinary group of specialists from around the world to develop the first clinical set of guidance for reproductive health care throughout the lifespan. I was the corresponding author for this guide, published in August 2026, that recommends providing age-appropriate education early and discussing reproductive health at least annually starting in the teen years. Women with CF: Pregnancy planning or prevention. Women with CF are becoming pregnant more often and, overall, doing better during pregnancy than Dallas might have expected years ago. CFTR modulators, first introduced in 2012, play an important role in this. Cystic fibrosis can cause cervical mucus to become unusually thick, creating a barrier that makes it more difficult for sperm to reach the uterus. CFTR modulator therapy can improve the cervical environment, which may help explain why fertility has increased. That is good news for women who want to become pregnant. And it also means that women who do not want to become pregnant should not assume having CF will prevent pregnancy. Choosing contraception. One misconception that persists is that women with CF do not need contraception. In reality, most have the same broad range of contraceptive options as anyone else. Lumacraftor/ivacaftor (Orkambi), an older and less commonly used CFTR modulator, can make hormonal contraception less effective. Most other CFTR modulators do not interfere with hormonal birth control. Patients should talk with a CF specialist and Ob/Gyn about which contraceptive method best fits their lifestyle, medications, and plans for pregnancy. If you're considering pregnancy, plan ahead. Patients who are considering pregnancy should visit with their CF specialist before trying to conceive. This gives patients an opportunity to optimize their health; the healthier they are going into pregnancy, the more smoothly Dallas expect that pregnancy to go. A preconception visit may include assessments to help manage or enhance: * Lung function and respiratory health * Nutrition and weight * CF-related diabetes or risk of diabetes * Medications and supplements * Other CF-related health conditions This also is the time to meet with a genetic counselor. Because CF is an inherited condition, patients and their partners should be offered carrier screening, ideally before pregnancy. This is a blood test that can estimate the chances a child might inherit cystic fibrosis or another genetic condition from their parents. If one or both parents have genetic variants that could cause CF, a genetic counselor can explain what this may mean for the pregnancy. They will also discuss options for reproductive genetic counseling, such as prenatal testing or in vitro fertilization (IVF) with preimplantation genetic testing. These conversations give patients data to make informed decisions for family planning. During pregnancy: Expect extra monitoring. Pregnancy for a woman with CF is still considered higher risk. Even though outcomes have improved substantially, there is still an elevated risk of certain complications, including premature birth and gestational diabetes. Visits. Patients will need more frequent visits with their CF team and obstetric team, which likely will include a maternal-fetal medicine specialist who is specially trained to manage a high-risk pregnancy. Dallas will closely monitor lung function, nutrition, weight gain, and medications and communicate about care throughout the pregnancy. Medication. Dallas know CFTR modulators and other CF medications cross the placenta, meaning the baby is exposed to the medication. However, stopping an effective modulator can cause the patient's own health to deteriorate. Do not stop taking CF medications unless the care team recommends it. Current drug safety evidence is reassuring. UT Southwestern has been involved in research to determine whether CF medications are safe for patients who are pregnant and breastfeeding and for their babies in the first two years after delivery. However, Dallas still have much to learn about long-term effects. Decisions about medication should be made between patients and their CF and obstetric teams. Blood sugar. CF can affect the pancreas and the body's ability to regulate blood sugar. About 30%-40% of adults with cystic fibrosis develop CF-related diabetes, and women with CF also are at increased risk of developing gestational diabetes. The new guidance recommends an oral glucose tolerance test before pregnancy and extra testing during pregnancy. Finding high blood sugar early gives Dallas the opportunity to treat it and reduce diabetes-related risks, such as high blood pressure during pregnancy, premature birth, and need for a C-section delivery. After delivery: Breastfeeding is increasingly an option. Breastfeeding requires additional calories, and maintaining adequate nutrition and weight has historically been challenging for many patients with CF. That picture is changing, too. Women whose nutrition is in a good place before pregnancy are increasingly tolerating both pregnancy and breastfeeding. CFTR modulators do pass into breast milk, so patients should discuss breastfeeding with their CF care team and the baby's pediatrician. Nutrition and weight also deserve close attention after delivery. Extra newborn screening for CF. Early research and case reports suggest that because CFTR modulators cross the placenta, babies with cystic fibrosis who are exposed to the drugs before birth may not be born with pronounced signs of CF. Some of the common signs include high levels of immunoreactive trypsinogen (IRT) in the blood, severe jaundice, salty skin, or severe neonatal constipation. Ironically, this promising development creates a new challenge: Traditional newborn screening may miss CF in a baby who is exposed to CFTR modulators in utero. When there is a possibility the baby may have inherited CF, genetic testing after birth can provide a clearer answer than newborn screening alone. * Raksha Jain, M.D. March 4, 2026 Men with CF: Fertility remains a challenge. While reproductive possibilities have changed dramatically for women with CF, the outlook is different for men. More than 95% of men with CF cannot conceive naturally because they are born without vas deferens - the tubes that carry sperm from the testes. Most male patients still produce sperm, but the sperm don't have a pathway out. Men with CF who want biological children generally need sperm retrieval combined with assisted reproductive technology such as IVF. But here, too, research is giving Dallas an intriguing glimpse into what the future can hold. CFTR modulators cannot restore a vas deferens that did not develop before birth. But because these drugs cross the placenta, a male fetus with CF may be exposed to the treatment when the reproductive system is developing. Several case reports have described boys with CF who were exposed to CFTR modulators before birth and were born with intact vas deferens. These are case reports, not large studies, so Dallas cannot yet say whether prenatal exposure will preserve fertility later in life. But it raises the possibility that the reproductive outlook for the next generation of men with CF could look very different. A new conversation about life with CF. The pace of change in cystic fibrosis care has been extraordinary. Reproductive health should no longer be an afterthought. Questions that once centered on survival and daily health now increasingly include family planning, pregnancy, and parenthood. The new guidance recommends introducing these topics early, revisiting them regularly, and giving patients ample information to decide whether, when, and how they want to become a parent. Women with cystic fibrosis are becoming pregnant more easily and having healthier pregnancies than many of Dallas would have imagined a generation ago. And research is beginning to ask questions that once would have seemed unthinkable - including whether treatment before birth could change the earliest effects of CF. The conversation is no longer just about managing cystic fibrosis today. Increasingly, it's about helping patients plan for the life they want to build tomorrow. To talk with an expert about cystic fibrosis care, make an appointment by calling 214-645-6616 or request an appointment online.
Carbon Biosciences (“Carbon”), a Longwood Fund founded biotech company and emerging leader in the development of novel parvovirus-derived gene therapies, tod...
Stonefire Grill partners with Cystic Fibrosis Foundation for fundraiser. September 9, 2026 · · Southern California diners can donate online or in-person to support breakthrough research. Stonefire Grill, a staple for scratch-made classic American meals and family-style dining for over 25 years, is launching a special fundraiser for the Cystic Fibrosis Foundation. Running from Sept. 9 through Oct. 6, the campaign invites guests across all Stonefire Grill and Rattler's Bar B Que locations in Southern California to contribute to research, drug development, and specialized care. To double the impact, Stonefire Grill and Rattler's Bar B Que will match guest contributions up to $5,000. How Stonefire Grill guests can participate. Diners visiting any store location can make a donation at the register. Each donor can write a personal message of encouragement on a blue ribbon, which will hang in the dining room to raise awareness for those impacted by cystic fibrosis. For folks who prefer pickup or home delivery, online orders placed directly through the Stonefire Grill or Rattler's Bar B Que websites feature a round-up option at checkout to support the cause. "In my 26 years with the Cystic Fibrosis Foundation, I've seen firsthand what CF means for people and families close to me," said David Youngberg, CEO of Stonefire Grill. "Bringing our restaurant communities together behind the Foundation's groundbreaking work is something I care deeply about. The blue ribbons in our restaurants are simple but powerful reminders that every contribution makes a difference, and that our guests are standing with the cystic fibrosis community in its goal of making CF stand for Cure Found." Advancing critical care and lifesaving science. Cystic fibrosis is a progressive, genetic condition affecting the lungs, pancreas, and other vital organs, impacting nearly 40,000 people in the United States across every demographic. The Cystic Fibrosis Foundation works to find a cure while helping individuals live longer, healthier lives by funding scientific research and delivering high-quality care. "The Cystic Fibrosis Foundation is deeply grateful for the support of Stonefire Grill," said Shaina Flesser, Executive Director of the Southern California Chapter of the Cystic Fibrosis Foundation. "Their generosity, alongside the CF community's efforts, will build on our work that has helped add decades of life for people with CF. We are focused on supporting people with CF no matter where they are on their journey and on pursuing a cure for all people with the disease." Join the campaign today. Southern California residents can take part in the initiative through Oct. 6. To find a nearby dining room, learn more about the campaign, or order online to round up your total, visit StonefireGrill.com. To discover more about the foundation's medical breakthroughs and programs, check out CFF.org. Discover more Cooking & Recipes
Find jobs on Simplify and start your career today
We update Cystic Fibrosis Foundation's jobs every few hours, so check again soon!Browse all jobs
Industries
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Bethesda, MD
Founded
1955
Find jobs on Simplify and start your career today
We update Cystic Fibrosis Foundation's jobs every few hours, so check again soon!Browse all jobs